Regeneron Pharmaceuticals, INC.
Forward trial catalysts linked to REGN
CSA tracks 4 forward catalysts for Regeneron Pharmaceuticals, INC. across 3 assets, spanning Phase 3. The nearest is a readout expected Mar 22, 2027 (day precision). Confidence across its tracked catalysts breaks down as 4 medium. Tracked indications include Melanoma, Advanced Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, and 6 more.
REGN in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Regeneron Pharmaceuticals, INC. has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
12 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| fianlimab | NCT05352672 | Phase 3 | Active, not recruiting | 2026-03-12 | Experimental | Regeneron Pharmaceuticals | Melanoma |
| fianlimab | NCT05608291 | Phase 3 | Active, not recruiting | 2026-07-27 | Experimental | Regeneron Pharmaceuticals | Melanoma |
| fianlimab | NCT06246916 catalyst | Phase 3 | Recruiting | 2027-03-22 | Experimental | Regeneron Pharmaceuticals | Melanoma |
| mibavademab | NCT07220772 catalyst | Phase 3 | Recruiting | 2027-06-18 | Experimental | Regeneron Pharmaceuticals | Monogenic Obesity |
| fianlimab | NCT05785767 catalyst | Phase 2/3 | Active, not recruiting | 2027-09-28 | Experimental | Regeneron Pharmaceuticals | Advanced Non-Small Cell Lung Cancer |
| odronextamab | NCT06091254 catalyst | Phase 3 | Recruiting | 2028-02-07 | Experimental | Regeneron Pharmaceuticals | Follicular Lymphoma (FL) |
| odronextamab | NCT06091865 | Phase 3 | Recruiting | 2028-03-30 | Experimental | Regeneron Pharmaceuticals | Diffuse Large B-cell Lymphoma (DLBCL) |
| odronextamab | NCT06230224 | Phase 3 | Active, not recruiting | 2028-05-29 | Experimental | Regeneron Pharmaceuticals | B-Cell Non-Hodgkin Lymphoma (B-NHL) |
| odronextamab | NCT06097364 | Phase 3 | Active, not recruiting | 2029-07-29 | Experimental | Regeneron Pharmaceuticals | Follicular Lymphoma (FL) |
| fianlimab | NCT05800015 | Phase 2/3 | Active, not recruiting | 2030-01-16 | Experimental | Regeneron Pharmaceuticals | Non-small Cell Lung Cancer |
| odronextamab | NCT06149286 | Phase 3 | Recruiting | 2031-04-30 | Experimental | Regeneron Pharmaceuticals | Relapsed/Refractory Follicular Lymphoma; Relapsed/Refractory Marginal Zone Lymphoma (R/R M… |
| odronextamab | NCT05991388 | Phase 2/3 | Recruiting | 2031-05-01 | Experimental | University of Birmingham | B-cell Non Hodgkin Lymphoma |
Every trial the CSA sample links to REGN's tracked assets, including trials another sponsor runs.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →